Journal of Medicinal Chemistry · 2020 · 72 citations · 24 references
PharmacyMedicinal ChemistryPharmacologyBioisosterismDrug DesignDrug DiscoveryAntiretroviral TherapyAntiviral Drug ResistanceAntiviral PharmacologyAntiviral ResistanceLead Compound DesignPotency OptimizationAntiviral Structure-activity RelationshipsDrug Resistance MutationsHiv Antiretroviral TherapyOptimization Of Pharmacokinetic PropertiesPhenotypic Resistance ProfilingResistance-associated MutationsSolubilityStructure - Pharmacokinetic Relationship Analysis
The development of efficacious NNRTIs for AIDS therapy commonly encountered the rapid generation of drug-resistant mutations, which becomes a major impediment to effective anti-HIV treatment. Using a structure-based bioisosterism strategy, a series of piperidine-substituted thiophene[2,3-d]pyrimidine derivatives were designed and synthesized. Compound 9a yielded the greatest potency, exhibiting significantly better anti-HIV-1 activity than ETR against all of the tested NNRTI-resistant HIV-1 strains. In addition, the phenotypic (cross)resistance of 9a and other NRTIs to the different selected HIV-1 strains was evaluated. As expected, no phenotypic cross-resistance against the NRTIs (AZT and PMPA) was observed with the mutant 9ares strain. Furthermore, 9a was identified with improved solubility, lower CYP liability, and hERG inhibition. Remarkably, 9a exhibited optimal pharmacokinetic properties in rats (F = 37.06%) and safety in mice (LD50 > 2000 mg/kg), which highlights 9a as a promising anti-HIV-1 drug candidate.
24
Alexander N. Katchman, John Koerner, Toshimasa Tosaka et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 137 citations · Full text
Dongwei Kang, Zengjun Fang, Zhenyu Li et al. · Journal of Medicinal Chemistry · 2016 · 135 citations · Full text